You are here

Article Text

Article menu

Download PDFPDF

Ovarian cancer
776 Role of optimal cytoreduction in advanced stage malignant ovarian germ cell tumors, data from the MITO-9 trial
Free
  1. A Bergamini1,
  2. C Cassani2,
  3. F Raspagliesi3,
  4. G Bogani3,
  5. L Bocciolone1,
  6. E Rabaiotti1,
  7. R Cioffi1,
  8. G Sabetta1,
  9. G Scarfone4,
  10. A Savarese5,
  11. MG Ferrandina6,
  12. F Mascilini6,
  13. G Cormio7,
  14. G Giorda8,9,
  15. S Pignata10,
  16. G Taccagni1 and
  17. G Mangili1
  1. 1IRCCS San Raffaele Hospital , Obstetrics and Gynecology, Milan
  2. 2Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
  3. 3Istituto Nazionale dei Tumori | Fondazione IRCCS, Milano, Italy
  4. 4Mangiagalli Clinic IRCCS Cà Granda Foundation Ospedale Maggiore Policlinico, Milano, Italy
  5. 5Ospedale Regina Elena, Roma, Italy
  6. 6Agostino Gemelli University Policlinic, Roma, Italy
  7. 7Ospedale Oncologico Giovanni Paolo II, Bari, Italy
  8. 8Aviano, Italy
  9. 9Oncology Referral Center, Aviano, Italy
  10. 10IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”

Abstract

Introduction/Background* the role of optimal cytoreduction in advanced stage MOGCTs is still a debated issue, considering the high chemosensitivity of these tumors and young patients’ age. The aim of the present study was to analyze the role of residual tumor at primary surgery in advanced stage MOGCTs.

Methodology clinicopathological data from patients with stage III-IV MOGCTs were retrospectively collected among MITO centers (Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies) and analyzed. All patients underwent primary surgery. Optimal cytoreduction was defined as macroscopic residual tumor=0. All patients received adjuvant platinum-based chemotherapy. Clinicopathological features were evaluated for association with relapse.

Result(s)*42 patients were included. 18 (42.8%) were affected by dysgerminomas, 24 (57.2%) by non-disgerminomatous MOGCTs. 24 patients (57.2%) achieved optimal cytoreduction at primary surgery (residual tumor=0). No statistical difference was detected in stage distribution, age, rate of optimal cytoreduction between the dysgerminomas and non dysgerminomatous groups. Median 5year- disease free survival (DFS) rates were 87.8% and 50.0% for dysgerminomas and non-dysgerminomas, respectively. In the whole cohort, there was no difference in terms of 5 years-DFS according to residual tumor at primary surgery (74.6% vs 56.0%, p=0.25). Residual tumor at primary surgery was a prognostic factor for DFS only for non-dysgerminomatous MOGCTs (64% vs 30% for optimal vs suboptimal cytoreduction, respectively, p=0.05).

Conclusion* in the present study, optimal cytoreduction at primary surgery was a prognostic factor affecting disease-free survival only for non-disgerminomatous MOGCTs.

https://doi.org/10.1136/ijgc-2021-ESGO.469

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.